Belmont Capital’s Biogen BIIB Stock Holding History

Belmont Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-75	Closed	-$18K	–	60
2020 Q4	$18K	Hold	75	–	–	0.01%	39
2020 Q3	$21K	Hold	75	–	–	0.01%	33
2020 Q2	$20K	Hold	75	–	–	0.01%	35
2020 Q1	$24K	Hold	75	–	–	0.02%	27
2019 Q4	$22K	Buy	+75	New	+$20.8K	0.02%	29

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Belmont Capital's BIIB Position: Q1 2021 in Review

Belmont Capital sold out of Biogen (BIIB) in Q1 2021, closing a stake of 75 shares — an estimated $18K sold.

Belmont Capital first reported a position in BIIB in Q4 2019 and held it in 5 quarters. The position peaked at $24K in Q1 2020. 1,094 funds tracked by Wall St. Rank hold BIIB as of Q1 2021.

Belmont Capital reported no remaining Biogen position as of Q1 2021 after selling out during the quarter.
Belmont Capital sold 75 Biogen shares in Q1 2021, an estimated $18K.
Belmont Capital first reported a position in Biogen in Q4 2019 and held it in 5 quarters.
Belmont Capital's Biogen position peaked at $24K in Q1 2020.
1,094 funds tracked by Wall St. Rank held Biogen as of Q1 2021.

Based on Belmont Capital's 13F filing for Q1 2021, filed 28 Apr 2021.